Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Utility of FET-PET in detecting high-grade gliomas presenting with equivocal MR imaging features.

Puranik AD, Boon M, Purandare N, Rangarajan V, Gupta T, Moiyadi A, Shetty P, Sridhar E, Agrawal A, Dev I, Shah S.

World J Nucl Med. 2019 Jul-Sep;18(3):266-272. doi: 10.4103/wjnm.WJNM_89_18.

2.

[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Göbel G, la Fougère C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G.

Neuro Oncol. 2013 Mar;15(3):341-51. doi: 10.1093/neuonc/nos300. Epub 2013 Jan 17.

3.

Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.

Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, Sabel M, Steiger HJ, Reifenberger G, Beez T, Coenen HH, Floeth FW, Langen KJ.

J Nucl Med. 2013 Feb;54(2):229-35. doi: 10.2967/jnumed.112.109603. Epub 2012 Dec 11.

4.

Cutoff value of choline concentration reliably reveals high-grade brain tumors among other contrast-enhancing brain lesions.

Porto L, Hattingen E, Stuecher A, Herminghaus S, Lanfermann H, Ulrich Pilatus UP.

J Neurol Surg A Cent Eur Neurosurg. 2012 May;73(3):147-52. doi: 10.1055/s-0032-1313723. Epub 2012 May 3.

PMID:
22190143
5.

Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.

Bette S, Gempt J, Delbridge C, Kirschke JS, Schlegel J, Foerster S, Huber T, Pyka T, Zimmer C, Meyer B, Ringel F.

World Neurosurg. 2016 May;89:230-9. doi: 10.1016/j.wneu.2016.01.085. Epub 2016 Mar 9.

PMID:
26855307
6.

Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy.

Floeth FW, Pauleit D, Wittsack HJ, Langen KJ, Reifenberger G, Hamacher K, Messing-Jünger M, Zilles K, Weber F, Stummer W, Steiger HJ, Woebker G, Müller HW, Coenen H, Sabel M.

J Neurosurg. 2005 Feb;102(2):318-27.

PMID:
15739561
7.

Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas.

Pyka T, Gempt J, Hiob D, Ringel F, Schlegel J, Bette S, Wester HJ, Meyer B, Förster S.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):133-141. doi: 10.1007/s00259-015-3140-4. Epub 2015 Jul 29.

PMID:
26219871
8.

Comparison of 18F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study.

Verger A, Filss CP, Lohmann P, Stoffels G, Sabel M, Wittsack HJ, Kops ER, Galldiks N, Fink GR, Shah NJ, Langen KJ.

Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2257-2265. doi: 10.1007/s00259-017-3812-3. Epub 2017 Aug 22.

PMID:
28831534
9.

Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study.

Verger A, Filss CP, Lohmann P, Stoffels G, Sabel M, Wittsack HJ, Kops ER, Galldiks N, Fink GR, Shah NJ, Langen KJ.

World Neurosurg. 2018 May;113:e727-e737. doi: 10.1016/j.wneu.2018.02.139. Epub 2018 Mar 3.

PMID:
29510293
10.

An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.

Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58. doi: 10.1016/j.ijrobp.2010.07.002. Epub 2011 May 11.

PMID:
21570201
11.

Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence.

Ewelt C, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, Stoffels G, Stummer W.

Clin Neurol Neurosurg. 2011 Sep;113(7):541-7. doi: 10.1016/j.clineuro.2011.03.008. Epub 2011 Apr 20.

PMID:
21507562
12.

Potential for differentiation of glioma recurrence from radionecrosis using integrated 18F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging: A prospective evaluation.

Sogani SK, Jena A, Taneja S, Gambhir A, Mishra AK, D'Souza MM, Verma SM, Hazari PP, Negi P, Jadhav GK.

Neurol India. 2017 Mar-Apr;65(2):293-301. doi: 10.4103/neuroindia.NI_101_16.

13.

Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.

Server A, Kulle B, Maehlen J, Josefsen R, Schellhorn T, Kumar T, Langberg CW, Nakstad PH.

Acta Radiol. 2009 Jul;50(6):682-9. doi: 10.1080/02841850902933123.

PMID:
19449234
14.

The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.

Jaber M, Wölfer J, Ewelt C, Holling M, Hasselblatt M, Niederstadt T, Zoubi T, Weckesser M, Stummer W.

Neurosurgery. 2016 Mar;78(3):401-11; discussion 411. doi: 10.1227/NEU.0000000000001020.

15.

Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool.

Lopez WO, Cordeiro JG, Albicker U, Doostkam S, Nikkhah G, Kirch RD, Trippel M, Reithmeier T.

Onco Targets Ther. 2015 Dec 17;8:3803-15. doi: 10.2147/OTT.S87126. eCollection 2015.

16.

Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.

Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, Naegele T, Ernemann U.

Invest Radiol. 2013 May;48(5):295-301. doi: 10.1097/RLI.0b013e31827188d6.

PMID:
23296081
17.

Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?

Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K.

J Nucl Med. 2006 Mar;47(3):393-403. Erratum in: J Nucl Med. 2006 May;47(5):806.

18.

The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.

Heinzel A, Müller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM, Galldiks N.

J Nucl Med. 2013 Aug;54(8):1217-22. doi: 10.2967/jnumed.113.120089. Epub 2013 Jun 19.

19.

The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen KJ.

Neuro Oncol. 2015 Sep;17(9):1293-300. doi: 10.1093/neuonc/nov088. Epub 2015 May 24.

20.

Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.

Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, Erdem Z, Shah NJ, Fink GR, Coenen HH, Langen KJ.

J Nucl Med. 2013 Dec;54(12):2046-54. doi: 10.2967/jnumed.113.123836. Epub 2013 Oct 24.

Supplemental Content

Support Center